NextCure director buys $53,691 of stock after 38% slide
Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash
ADAR1 Capital Management, a 10% owner and director of NextCure (NASDAQ:NXTC), purchased 10,851 shares for $53,691 across three days in late October, at prices from $4.8294 to $5.0953. The buying follows a 38% decline in the stock over six months, even as an InvestingPro Fair Value analysis suggests shares may be overvalued.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.